NIJMEGEN, Netherlands, Oct. 13, 2015 /PRNewswire/ — EndoStim, a medical device company developing neurostimulation therapy for gastroesophageal reflux disease (GERD), announced today that InEK, the German Institute for the Hospital Remuneration System, has decided to approve the request of DGVS (German Society for Digestive and Metabolic Diseases) and assign a permanent DRG (Diagnosis Related Group)1 code covering reimbursement for EndoStim therapy to treat GERD in Germany.2
http://www.prnewswire.com/news-releases/endostims-neurostimulation-therapy-for-gerd-receives-permanent-reimbursement-coverage-in-germany-300158730.html
EndoStim's neurostimulation therapy for GERD receives permanent reimbursement coverage in Germany